Upstream Bio Inc (UPB) Straddle

Trading a UPB straddle lets you take a pure volatility position on Upstream Bio Inc without committing to a direction. Upstream Bio Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate UPB straddle pricing in real time and find the moments when expected moves are mispriced.

A long straddle on UPB profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Upstream Bio Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the UPB straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Earnings, product cycles, macro prints — any time volatility itself is the trade, the UPB straddle is the cleanest expression of that view. Our scanner prices every UPB straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a UPB straddle into a catalyst or short a UPB straddle to harvest decay, the options straddle setups that matter are all in one place.